Wearable Healthcare Devices Market worth US$75.98 billion by 2030 with 10.9% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Sept. 8, 2025 /PRNewswire/ -- The global Wearable Healthcare Devices Market, valued at US$41.07 billion in 2024,...
Pharmaceutical
Fitness Tracker Market is expected to generate a revenue of USD 189.98 Billion by 2032, Globally, at 17.50% CAGR: Verified Market Research®
The Fitness Tracker Market is driven by increasing health consciousness, rising adoption of wearable technology, and integration with mobile health...
Hospital PMI® at 51.3%; August 2025 ISM® Hospital PMI® Report
TEMPE, Ariz., Sept. 8, 2025 /PRNewswire/ -- Economic activity in the hospital subsector expanded in August for the second month...
Glencoe Software, Leader in Bioimaging Data Solutions, Announces Executive Transition and Commitment to Innovation
SEATTLE and DUNDEE, United Kingdom, Sept. 8, 2025 /PRNewswire/ -- Glencoe Software builds industry-leading, global data solutions for the world's...
Xtalks Named Media Partner for KP Morgan’s 9th Operational Excellence in Clinical Trials Summit in Toronto
Xtalks is proud to serve as an official Media Partner for the 9th Operational Excellence in Clinical Trials (OECT) Summit,...
Successfully Moving from On-Premises QMS to SaaS eQMS, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn why moving from an on-premises quality management system (QMS) to a cloud-based (SaaS) electronic QMS...
CGT Oncology Trials: IRB/IBC Strategies, Trends and Operational Insights, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into proven IRB/IBC strategies that streamline regulatory compliance and keep cell and gene therapy...
Desert Oasis Healthcare’s Dr. Brian Hodgkins to Share Expertise at California Society of Health-System Pharmacists Seminar 2025
Sharing Over 30 Years of Pharmacy Leadership, Dr. Hodgkins Represents DOHC at CSHP Seminar CHULA VISTA, CA / ACCESS Newswire...
SOLSTICE HEALTH Ranks No. 1520 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
With Three-Year Revenue Growth of 287% Percent, This Marks Solstice Health's 1st Time on the List OCONOMOWOC, WISCONSIN / ACCESS...
Medical Care Technologies Inc. (OTC PINK:MDCE) Slashes Outstanding Share Count by 680,000,000 Shares
MESA, ARIZONA / ACCESS Newswire / September 8, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) (the "Company" or "MDCE")...
MediciNova Provides Shareholder Update on Key Developments
LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody- Safety profile observed in first four dose cohorts supports...
From Telehealth to Trust: Flash Survey of WHX Attendees on the Next Wave of Middle East Digital Health Startups
Independent Black Book Findings on Compliance, Consent, and Patient Engagement from WHX Dubai Attendees DUBAI, AE / ACCESS Newswire /...
CS Diagnostics Corp. Submits Patent Application For CS-Protect Hydrogel in the US Market
PARTNERING WITH PAUL & ALBRECHT PATENT LAWYERS CHEYENNE, WYOMING / ACCESS Newswire / September 8, 2025 / CS Diagnostics Corp....
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for...
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September...
Pelthos Therapeutics to Participate in Upcoming September Investor Conferences
DURHAM, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company (“Pelthos” or the...
Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled
On Track To Be First Mover In $7Bn Addressable Market With No Current Therapeutic OptionsBy: Benzinga Staff Writer CARDIFF, UK...
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response...
CorMedix Announces Strategic Minority Investment in Talphera
BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing...